reason report
pt
vertex reimburs agreement nh england link
expect compani ou sale orkambi symkevi
increas materi start result increas
sale expect ultim addit patient
approxim per patient per year revenu forecast
increas flow higher
ep basi increas price target vertex
maintain market perform rate compani
stock penetr addit patient
homozyg like rel quick uk
manag estim penetr rate subgroup
patient reach us although agreement secur
reimburs access vertex doublet still leav
tripl combin fate air uk suggest us
tripl may reimburs incorpor
time updat model expect uk govern pay
vertex medicin materi
us germani price ultim also appli
pt increas driven higher ou sale forecast reiter
mp base updat cf market model vertex compani
model global cf revenu forecast increas
ou forecast increas
higher revenu forecast driven
higher expect sale orkambi symkevi uk
largest popul cf patient us ou orkambi
sale forecast increas
ou symkevi forecast nearli flat
increas kalydeco ou forecast slightli
decreas due price headwind
uk increas benefit larger
address patient popul reimburs approv
mutat includ tripl combin forecast come
ex us market due expect later approv
reimburs uk base chang increas
price target reiter market perform
rate stock
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target vertex rate stock market perform vertex
clear clinic develop hurdl introduc medicin treat
patient cystic fibrosi cf believ market fairli valu vertex cf
portfolio loss exclus vertex launch success iter cf
medicin cloud disput price access delay reimburs
europ result success reduct revenu forecast compani
expect vertex cf revenu line grow steadili
compar consensu expect believ vertex geograph revenu mix
continu heavili weight us due continu resist
payer europ probabl success recent approv tripl combin
valuat account full expect valu cf portfolio well
risk-adjust opportun compani effort antitrypsin defici aatd even
posit view dcf valuat incorpor sustain oper
margin requir consider disciplin compani
reput frugal incorpor premium price
target recogn vertex might one attract larg cap growth asset
sector howev view reason acquisit premium would put compani cost
nearli like difficult pill swallow dilution-avers larg
addit patient get access vertex medicin uk
accord uk cystic fibrosi registri annual data report cf patient
uk total homozyg mutat patient
treat orkambi symkevi younger younger
base datapoint current address orkambi symkevi patient popul
uk estim may increas hundr futur younger
patient cover reimburs assum peak penetr rate
subgroup patient uk compar us
eu approv expect late earli tripl combin
anticip uk reimburs approv late earli
base research ema took averag month approv vertex
medicin kalydeco month orkambi month symkevi month exhibit
assum vertex submit eu regulatori file end year eu approv like
late earli howev timelin secur reimburs approv uk
less predict appear condit complet nice review current
assum tripl secur reimburs uk sooner start
increment patient volum help vertex individu patient profit
significantli lower us given believ price doublet
combin ultim tripl uk negoti price
disclos expect uk pay doublet
like tripl combin well price rang materi lower germani
usa price rang germani usa importantli uk price may
also subject eros patient volum increas mutat
age cohort treatment-elig model assum annual price eros
uk compar us rest world
global sale forecast ou market
base updat cf market model vertex compani model global cf revenu
forecast increas ou forecast increas
forecast global cf sale reach
import ex us market increas estim
percentag global sale reach steadili grow reach
long term
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
eu filingelaps time month approv euelaps time month reimburs ukkalydeco timelin triplet base averag elaps time cf product vertex incorpor
nvo azn appli current ep estim
discount back year compani cost equiti give valu one year
use averag mid larg cap biotech price-to-revenu multipl sale
appli revenu estim post-
tripl discount back year compani cost equiti give valu one year
lastli dcf valuat given wacc termin cash flow growth rate
give present valu averag three method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit compani cf medicin
particularli orkambi symdeko newli approv tripl combin medicin trikafta
major risk disappoint delay failur compani develop
regulatori file tripl combin geographi outsid us risk includ
continu lack access reimburs vertex medicin acceler success
develop altern modul cf tr altern approach treat cf
gene therapi final compani histori spend much potenti earn
expens diversifi acquisit could undermin futur expect valu compani
cf portfolio opportun better-than expect perform includ realiz signific
revenu compani current cf dual combin market outsid us well
acceler commerci adopt tripl combin regimen remain cautiou
prospect futur contribut vertex non-cf develop program much
valu program risk develop delay disappoint competit pre-
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
brand
type event
event trial detail
date known
up/down
expect
ema file cf patient year old
report clinic data peopl two
mutat
evalu abil reduc protein
level urin
svb leerink llc research compani file
million
product sale po adjust
trikata tripl comb ivacaftor tezacaftor elexacaftor approv
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal
current averag growth larg cap biopharma multipl ep nvo
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
